Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg
L Stump

Showing results (31-40 of 464) with videos related to

Pageof 47
Sort By:
Nature Medicine|September 1, 2025
Semaglutide targets MASH molecular pathways beyond weight lossMaurice Michel, Jörn M Schattenberg
European Radiology|January 27, 2022
Refining imaging tools to detect advanced fibrosis: could liver surface nodularity address an unmet need in the NAFLD epidemic?Jörn M Schattenberg, Tilman Emrich
Alimentary Pharmacology & Therapeutics|December 28, 2023
Editorial: Does knowledge about liver disease enhance adherence to lifestyle recommendations?Maurice Michel, Jörn M Schattenberg
Hepatology (Baltimore, Md.)|November 26, 2009
Shortcut to deathJörn M Schattenberg, Marcus Schuchmann
Liver International : Official Journal of the International Association for the Study of the Liver|March 29, 2023
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK BiobankJoost Boeckmans, Jörn M Schattenberg
Current Opinion in Lipidology|October 18, 2011
Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemicJörn M Schattenberg, Detlef Schuppan
The Lancet. Gastroenterology & Hepatology|October 8, 2023
Uncouplers of mitochondrial oxidation in non-alcoholic fatty liver diseaseMaurice Michel, Jörn M Schattenberg
Nutrients|July 2, 2021
Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary ApproachesAngelo Armandi, Jörn M Schattenberg
Alimentary Pharmacology & Therapeutics|June 25, 2021
Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-the role for non-invasive testingTilman Emrich, Jörn M Schattenberg
JHEP Reports : Innovation in Hepatology|June 17, 2025
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLDJörn M Schattenberg, Jacob George
Pageof 47

Showing results (31-40 of 464) with videos related to

Sort By:
Pageof 47
Nature Medicine|September 1, 2025
Semaglutide targets MASH molecular pathways beyond weight lossMaurice Michel, Jörn M Schattenberg
European Radiology|January 27, 2022
Refining imaging tools to detect advanced fibrosis: could liver surface nodularity address an unmet need in the NAFLD epidemic?Jörn M Schattenberg, Tilman Emrich
Alimentary Pharmacology & Therapeutics|December 28, 2023
Editorial: Does knowledge about liver disease enhance adherence to lifestyle recommendations?Maurice Michel, Jörn M Schattenberg
Hepatology (Baltimore, Md.)|November 26, 2009
Shortcut to deathJörn M Schattenberg, Marcus Schuchmann
Liver International : Official Journal of the International Association for the Study of the Liver|March 29, 2023
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK BiobankJoost Boeckmans, Jörn M Schattenberg
Current Opinion in Lipidology|October 18, 2011
Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemicJörn M Schattenberg, Detlef Schuppan
The Lancet. Gastroenterology & Hepatology|October 8, 2023
Uncouplers of mitochondrial oxidation in non-alcoholic fatty liver diseaseMaurice Michel, Jörn M Schattenberg
Nutrients|July 2, 2021
Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary ApproachesAngelo Armandi, Jörn M Schattenberg
Alimentary Pharmacology & Therapeutics|June 25, 2021
Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-the role for non-invasive testingTilman Emrich, Jörn M Schattenberg
JHEP Reports : Innovation in Hepatology|June 17, 2025
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLDJörn M Schattenberg, Jacob George
Pageof 47